We are IntechOpen, the world’s leading publisher of Open Access books
Built by scientists, for scientists

6,600
Open access books available

177,000
International authors and editors

195M
Downloads

154
Countries delivered to

TOP 1%
Our authors are among the most cited scientists

12.2%
Contributors from top 500 universities

WEB OF SCIENCE™
Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com
1. Introduction

Neuroblastoma (NB) is a childhood neoplasm and the cause of ~15% of cancer deaths in children. The clinical behavior of NB is highly variable. While some tumors are easily treatable, nearly 50% of the tumors exhibit very aggressive behavior. The latter tumors are classified as high-risk NB and are characterized by widespread tumor dissemination and poor long-term survival. Determining the prognosis of NBs at the time of diagnosis is important because of the clinical heterogeneity of the disease. Current prognostic factors used by the COG (Children’s Oncology Group) Neuroblastoma Study for patient stratification and protocol assignment include: Age (<18 months vs >18 months), Stage (1, 2, 4S vs 3, 4), MYCN status (amplification vs non-amplification), Ploidy (diploid vs hyperdiploid), International Neuroblastoma Pathology Classification (Shimada system: Favorable vs Unfavorable Histology), 1pLOH (present vs absent), and 11qLOH (present vs absent) [1-3]. About half of high-risk NBs exhibit MYCN amplification, which is associated with older age, rapid tumor progression, and the worst prognosis [4]. According to the International Neuroblastoma Pathology Classification, NBs exhibiting MYCN amplification have unique histologic features, namely, an undifferentiated/poorly differentiated appearance and a high mitosis-karyorrhexis index. Nonetheless, certain NB with these histologic characteristics do not show MYCN amplification [5]. A previous report suggests that in non-MYCN-amplified unfavorable NB tumors, MYC rather than MYCN expression is responsible for the aggressive phenotype [6].

Current treatment for high-risk NB includes high dosage cytotoxic chemotherapy or myeloablative cytotoxic therapy with autologous hematopoietic stem cell transplantation [7]. Late relapse is often seen in patients with high-risk NB despite achieving a complete clinical remission. A subset of high-risk NBs, which is refractory to current front-line therapy designed for high-risk NB, is termed ultra high-risk NB [8, 9]. These tumors are totally unresponsive to current therapies, and thus reliable diagnostic tools to identify ultra high-risk NB prior to
treatment and innovative and effective therapeutic agents against these NBs are in need of development.

In this article, we will discuss our recent study on neuroblastoma stem cells, histopathological characteristics of these cells, and why the knowledge gained would help improve diagnosis and treatment of children with the most malignant NBs. We have recently reported the establishment of phenotypically stabilized stem cell-like NB cells (referred to as iCSC, see below) by short-term treatments of conventional monolayer NB cell lines with epigenetic modifiers [10]. The study addresses a fundamental problem that has affected a complete success in treating patients with cancers. Cancer stem cells (CSCs) are plastic in nature, a characteristic that hampers cancer therapeutics. To date, two models have been proposed to explain the existence of cancer stem cells in a tumor mass: the stochastic model and the hierarchical model.

According to the stochastic model, transformed single cells develop unlimited proliferative capability to cause a tumor. Initially, a single or few transformed cells result in uncontrolled growth. Accumulations of different mutations then occur driving additional tumor growth and resulting in heterogeneous subpopulations within the tumor. These cancer cells are believed to participate in tumor growth, develop resistance, and cause recurrence. Hence, all cells are considered tumorigenic and are targets for treatment. In contrast, the hierarchical or current CSC model states that in a given tumor, there exists a population of cancer cells that have characteristics similar to stem cells. Cancer stem cells have the capacity to renew indefinitely, to initiate tumor formation, and to give rise to multiple non-tumorigenic progenies via asymmetric cell division. As a result of this phenotypic drift, an established tumor would always consist of a mixture of CSC and non-CSC. Current anti-cancer therapies are believed to target the more differentiated tumor cells, but not the CSC component, which is ultimately responsible for tumor recurrence. Based on the most current thinking, the two models are not mutually exclusive.

To create phenotypically stabilized stem cell-like NB cells, our approach includes a short-term treatment (i.e., five days) of NB monolayer cell lines (SKNAS, SKNBE(2)C, CHP134, SY5Y) with either an inhibitor of DNA methylation and/or an HDAC inhibitor followed by cell culturing in the sphere-forming medium without the epigenetic modifiers. This strategy not only significantly augments the expression of the Yamanaka reprogramming factors and stem cell markers in the NB spheres generated, but it also captures these spheres in the “totally undifferentiated status” over a long period of time in vitro and in vivo. To date, known stemness/reprogramming factors include MYC/MYCN, SOX2, OCT4, NANOG, LIN28, and KLF4. These factors were shown to initiate reverse differentiation or reprogramming of somatic cells [11-13]. In addition, several stem cells markers (CD133, CXCRI4, ABCG2) [14-16] and neural crest stem cell markers (p75NTR, SOX9, SOX10, SLUG, Musashi-1, CD24, and HES1) have been reported [17-22].

The stem cell-like NB cells that are created in our recent study are characterized by their high expression of stemness factors, stem cell markers, and their open chromatin structure. We referred to these cells as induced CSC (iCSC) [10]. Our in vivo studies show that the NB iCSCs possess a high tumor-initiating ability and a high metastatic potential. SKNAS iCSC and SKNBE(2)C iCSC clones (as few as 100 cells) injected subcutaneously into SCID/Beige mice
formed tumors, and in one case, SKNBE(2)C iCSC metastasized to the adrenal gland, suggesting their increased metastatic potential [10]. Important histopathological observations were also made on the NB iCSC xenografts, and highlights of these findings are described in below.

The NB iCSC xenografts resemble human totally undifferentiated “Large-Cell” NB, the most aggressive and deadly form of NB. Histologically, NBs are classically divided into undifferentiated (UD), poorly differentiated (PD) and differentiating (D) subtypes. However, a unique histological subset of NBs within the UD and PD subtypes has been identified in the past years [5, 23]. These tumors are uniformly composed of large cells with sharply outlined nuclear membranes and one to four prominent nucleoli, and are referred to as “Large-Cell Neuroblastomas” or LCNs. Most importantly, the LCNs are the most aggressive and deadly tumors among the unfavorable NBs. Patients with the UD neuroblastoma and with the LCN appearance had a very poor prognosis regardless of age at diagnosis, clinical stage, and DNA index. Surprisingly, non-MYCN amplified UDs behaved significantly worse than MYCN amplified UDs [24]. As described below, our recent study demonstrates that NB iCSC xenografts do in fact resemble human LCN. In addition, there are histological differences between NB monolayer cell xenografts and iCSC xenografts.

As shown in Fig. 1, the SKNAS monolayer cell xenografts presented a mosaic pattern and were composed of two distinct components having different cellular morphologies. Tumor cells in the first component were larger cells. Tumor cells in the other component were smaller in both cellular and nuclear size and had smaller nucleoli. These small tumor cells often produced neurites or neuropils (indicated by the arrows). The monolayer cell xenografts were thus classified as poorly differentiated NB. In contrast, iCSC xenografts were composed of uniformly large cells with vesicular nuclei and one or more prominent nucleoli, and thus were classified as totally undifferentiated “large-cell” NB. Adapted from Fig. 4 of Ikegaki et al., [10].
in both cellular and nuclear size, and had smaller nucleoli (Fig. 1, upper left panel). Furthermore, these small tumor cells in the second component had reduced activities of mitosis and karyorrhexis (either intermediate MKI of 100~200/5,000 cells or low MKI of <100/5,000 cells) and often produced neurites or neuropils (Fig. 1, lower left panel). In addition, these smaller cells do not express MYC (Fig. 2). The monolayer cell xenografts were thus classified as poorly differentiated NB. In contrast, the SKNAS iCSC xenografts were composed of medium-sized, rather uniform cells with a large vesicular nucleus and one or few prominent nucleoli (Fig. 1 right panel). Mitotic and karyorrhectic activities were frequently encountered (either intermediate MKI of 100–200/5,000 cells or high MKI of >200/5,000 cells). The iCSC xenografts were thus classified as totally undifferentiated “large-cell” NB, according to the International Neuroblastoma Pathology Classification [2, 3, 23, 25]. In fact, as reported in our study, all of the other iCSC xenografts from SKNBE(2)C, CHP134, and SY5Y have the

---

**Figure 2.** Immunohistochemical examination of SKNAS monolayer cell xenografts for MYC expression. As shown in Fig. 1, the SKNAS monolayer cell xenografts were composed of two distinct components having different cellular morphologies. The smaller tumor cells had reduced activities of mitosis and karyorrhexis (see also text). Accordingly, immunohistochemical examination of SKNAS monolayer cell xenografts with the anti-MYC antibody showed that the smaller tumor cells lacked MYC expression.

**Figure 3.** Histopathological examinations of SKNAS iCSC xenografts and the human large-cell” NBs. H&E stained sections showed that the SKNAS iCSC xenografts resembled human undifferentiated “large-cell” NBs histologically. Adapted from Fig. 5 of Ikegaki et al., [10].
LCN phenotype [10]. Fig. 3 shows a remarkable resemblance of SKNAS iCSC xenografts and human LCN histologically.

MYC/MYCN expression and CXCR4 expression in NB monolayer cell xenografts and iCSC xenografts. Monolayer NB cell lines in culture express high levels of MYC (non-MYCN amplified cells) or MYCN (MYCN amplified cells). In consistent with this, our immunohistochemical analysis demonstrate that all NB monolayer cell xenografts and iCSC xenografts express high levels of MYC (SKNAS, SY5Y) or MYCN (SKNBE(2)C, CHP134)[10]. Fig. 4 shows a representative data of SKNBE(2)C.

In contrast to the consistently high MYC/MYCN expression, among the NB xenografts examined, there is a differential expression of CXCR4 in the SKNAS iCSC xenografts over monolayer cell counterparts (Fig. 5). It should be mentioned that both the larger and smaller cells of the SKNAS monolayer cell xenografts described in Fig. 1 were negative for CXCR4 staining, except some rare cases where a few cells were focally positive for CXCR4 staining (Fig. 5). These observations suggest that the large cells in SKNAS iCSC xenografts had different molecular and biological characteristics from the larger cells in the monolayer cell xenografts. However, the pattern of CXCR4 expression observed among the SKNAS xenografts was not always seen among the other iCSCs. Xenografts from both iCSC and monolayer cells of SKNBE(2)C, CHP134, SY5Y were all positive for CXCR4, but the staining in these cases was not intense and uniform [10].
Nestin expression in NB monolayer cell xenografts and iCSC xenografts.

Nestin is a type VI intermediate filament protein, and nestin expression has been suggested to be a NB stem cell marker [26, 27]. Nonetheless, our data showed that nestin is expressed in SKNAS iCSC xenografts, and in both the smaller cells and larger cells of SKNAS monolayer cell-xenografts (Fig. 6). This pattern of nestin expression together with the fact that the smaller cells of SKNAS monolayer xenografts are MYC negative (Fig. 2), nestin expression may therefore not serve for a specific marker of NB stem cells.

p75\textsuperscript{NTR} expression in NB monolayer cell xenografts and iCSC xenografts.

p75\textsuperscript{NTR} is the low-affinity nerve growth factor receptor and a neural crest stem cell marker [18]. Our in vitro study show
that SKNAS iCSC, SKNBE(2)C iCSC, and SY5Y iCSC express high levels of p75\textsuperscript{NTR} [10], and these observations are confirmed by the xenograft data shown in Fig. 7. As described in our study, the expression of p75\textsuperscript{NTR} in CHP 134 iCSC xenograft was minimal [10]. Interestingly, the pattern of p75\textsuperscript{NTR} expression in the SKNAS monolayer cell xenografts suggests that p75\textsuperscript{NTR} expression is not related to neuronal differentiation in NB (Fig. 8).
The expression of p75\textsubscript{NTR} is not related to neuronal differentiation in NB. Varying numbers of cells were positive for p75\textsubscript{NTR} in SKNAS monolayer cell xenografts. However, in the SKNAS monolayer cell xenografts, the cells with active neuropil formations were negative for p75\textsubscript{NTR} staining as indicated by arrows. Microscopic magnification of 400X was used for four pictures in the first and second rows, and 100X was used for two pictures in the bottom row. Adapted from Fig. 8 of Ikegaki et al., [10].
2. Conclusion

In conclusion, the xenografts established from the NB iCSCs shared two consistent and common features: the LCN phenotype and high-level MYC/MYCN expression. In addition, our observations suggest that NB cells with large and vesicular nuclei, representing their open chromatin structure, are indicative of stem cell-like tumor cells, and that epigenetic changes may have contributed to the development of these most malignant NB cells. These observations have significant clinical implications. Specifically, one may identify the most malignant and aggressive type of NBs that require immediate innovative therapeutic intervention by examining histological/cytological appearance of the tumor, namely totally undifferentiated large-cell NB with prominent nuclei and high-level expression of MYC and/or MYCN by immunohistochemical analysis. Finally, the availability of the NB iCSCs will serve as useful tools to develop effective anti-CSC agents for NB in vivo and will help improve treatment and cure for children with neuroblastoma.

Acknowledgements

Dr. Xiao Tang is supported by grants from NIH CA97255, CA127571, and a grant from the St. Baldrick Foundation. We would like to acknowledge Dr. Naohiko Ikegaki for his significant contribution in the development and establishment of the iCSCs described in this study and Jonathan Harbert for his technical assistance with the immunohistochemistry analyses.

Author details

Xiao X. Tang¹ and Hiroyuki Shimada²

1 Department of Anatomy and Cell Biology, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA

2 Department of Pathology & Laboratory Medicine, Children’s Hospital Los Angeles and University of Southern California Keck School of Medicine, Los Angeles, California, USA

References

[1] Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, Mosseri V, Simon T, Garaventa A, Castel V, Matthey KK; INRG Task Force. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009;27(2) 289-297.
[2] Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer 1999;86(2) 349-363.

[3] Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, Strom DO, Gerbing RB, Lukens JN, Castleberry RP. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999;86(2) 364-372.

[4] Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, Hammond D. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. New England Journal of Medicine 1985;313(18) 1111-1116.

[5] Kobayashi C, Monforte-Munoz HL, Gerbing RB, Strom DO, Matthay KK, Lukens JN, Seeger RC, Shimada H. Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index. Cancer 2005;103(1) 174-180.

[6] Fredlund E, Ringner M, Maris JM, Pahlman S. High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma. Proc Natl Acad Sci U S A 2008;105(37) 14094-14099.

[7] Matthay KK, Villablanca JG, Seeger RC, Strom DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group. N Engl J Med 1999;341(16) 1165-1173.

[8] Katzenstein HM, Cohn SL, Shore RM, Bardo DM, Haut PR, Olszewski M, Schmoldt J, Liu D, Rademaker AW, Kletzel M. Scintigraphic response by 123I-metaiodobenzylguanidine scan correlates with event-free survival in high-risk neuroblastoma. J Clin Oncol 2004;22(19) 3909-3915.

[9] Naranjo A, Parisi MT, Shulkin BL, London WB, Matthay KK, Kreissman SG, Yanik GA. Comparison of (1)(2)(3)I-metaiodobenzylguanidine (MIBG) and (1)(3)(1)I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer 2011;56(7) 1041-1045.

[10] Ikegaki N, Shimada H, Fox AM, Regan PL, Jacobs JR, Hicks SL, Rappaport EF, Tang XX. Transient treatment with epigenetic modifiers yields stable neuroblastoma stem cells resembling aggressive large-cell neuroblastomas. Proc Natl Acad Sci U S A 2013;in press.

[11] Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131(5) 861-872.
[12] Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126(4) 663-676.

[13] Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007;318(5858) 1917-1920.

[14] Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heschken C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007;1(3) 313-323.

[15] Ho MM, Ng AV, Lam S, Hung JY. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 2007;67(10) 4827-4833.

[16] Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003;63(18) 5821-5828.

[17] Kim J, Lo L, Dormand E, Anderson DJ. SOX10 maintains multipotency and inhibits neuronal differentiation of neural crest stem cells. Neuron 2003;38(1) 17-31.

[18] Morrison SJ, White PM, Zock C, Anderson DJ. Prospective identification, isolation by flow cytometry, and in vivo self-renewal of multipotent mammalian neural crest stem cells. Cell 1999;96(5) 737-749.

[19] Nieto MA, Sargent MG, Wilkinson DG, Cooke J. Control of cell behavior during vertebrate development by Slug, a zinc finger gene. Science 1994;264(5160) 835-839.

[20] Sakakibara S, Imai T, Hamaguchi K, Okabe M, Aruga J, Nakajima K, Yasutomi D, Nagata T, Kurihara Y, Uesugi S, Miyata T, Ogawa M, Mikoshiba K, Okano H. Mouse-Musashi-1, a neural RNA-binding protein highly enriched in the mammalian CNS stem cell. Dev Biol 1996;176(2) 230-242.

[21] Scott CE, Wynn SL, Sesay A, Cruz C, Cheung M, Gomez Gavirio MV, Booth S, Gao B, Cheah KS, Lovell-Badge R, Briscoe J. SOX9 induces and maintains neural stem cells. Nat Neurosci 2010;13(10) 1181-1189.

[22] Ohtsuka T, Ishibashi M, Gradwohl G, Nakashima S, Guillemot F, Kageyama R. Hes1 and Hes5 as notch effectors in mammalian neuronal differentiation. EMBO J 1999;18(8) 2196-2207.

[23] Tornoczky T, Kalman E, Kajtar PG, Nyari T, Pearson AD, Tweddle DA, Board J, Shimada H. Large cell neuroblastoma: a distinct phenotype of neuroblastoma with aggressive clinical behavior. Cancer 2004;100(2) 390-397.

[24] Wang LL, Sugaruna R, Tovar JP, Naranjo A, London WB, Hogarty MD, Gastire-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Shimada H. Neuroblastoma, Undifferentiated subtype: A report from the Children’s Oncology Group. Pediatric Dev Pathol 2012;in press.
[25] Tornoczky T, Semjen D, Shimada H, Ambros IM. Pathology of peripheral neuroblastic tumors: significance of prominent nucleoli in undifferentiated/poorly differentiated neuroblastoma. Pathol Oncol Res 2007;13(4) 269-275.

[26] Mahller YY, Williams JP, Baird WH, Mitton B, Grossheim J, Saeki Y, Cancelas JA, Ratner N, Cripe TP. Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus. PLoS ONE 2009;4(1) e4235.

[27] Thomas SK, Messam CA, Spengler BA, Biedler JL, Ross RA. Nestin is a potential mediator of malignancy in human neuroblastoma cells. J Biol Chem 2004;279(27) 27994-27999.